QIAGEN's QuantiFERON®-TB Access development program gains recognition from United Nations initiative for health innovation
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that QuantiFERON®-TB Access, a new solution unde…
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that QuantiFERON®-TB Access, a new solution unde…
Clinical study demonstrates proof-of-concept for active personalized immunotherapy approach in a pioneering multi-center…
The prospect of an actively personalized approach to the treatment of glioblastoma has moved a step closer with the rece…
NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by tar…
ESPRESSO — the Echelle SPectrograph for Rocky Exoplanet and Stable Spectroscopic Observations — has passed ESO’s Prelimi…
The International Team for Implantology (ITI), a leading academic organization dedicated to the promotion of evidence-ba…
While we often hear about smart, sustainable cities, adding smartness to an existing urban environment or developing a S…
A new high-performance liquid chromatography (HPLC) column designed for reversed-phased chromatography separation of mon…
. - Regulatory authority approves clinical trial for Glioma Actively Personalized Vaccine Consortium (GAPVAC) - First…
Die Freisetzung chemischer Substanzen, die die Ozonschicht gefährden, ist seit 1987 im Montreal- Protokoll geregelt. Sei…